[A21-56] Ipilimumab (NSCLC) - Addendum to Commission A20-116

Last updated 04.06.2021

Project no.:
A21-56

Commission:
Commission awarded on 29.04.2021 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

First-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitizing EGFR mutation or ALK translocation

Result of dossier assessment:

Patients with PD-L1 expression (TPS) ≥ 50%: added benefit not proven.

Patients with PD-L1 expression (TPS) < 50% and brain metastases: indication of an added benefit; extent “considerable”.

Patients with PD-L1 expression (TPS) < 50% without brain metastases: indication of an added benefit; extent “minor”.

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2021.06.04 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form